?Transgenic Gene Knockout Shared Resource Genetically modified mice are invaluable for SJCCC researchers to evaluate gene function in vivo and determine how specific genes regulate cell growth and differentiation in normal and tumor tissue. The Transgenic Gene Knockout Shared Resource (TGKSR) centralizes services for the generation of genetically modified mice and provides education, expertise, and cost effectiveness that would be extremely difficult to maintain in individual laboratories. The TGKSR Director is Hartmut Berns, PhD, an expert in transgenic technology with 23 years' experience creating genetically engineered mice, 16 years thereof in the management of transgenic cores at Comprehensive Cancer Centers. He is supported by 5 full-time technologists who employ state-of-the-art gene- modification technologies to produce transgenic mice by pronucleus injection of DNA into zygotes, ESC-based gene-targeted mice by injection of genetically engineered ESCs into blastocyst-staged embryos, and gene- edited mice. Engineered mice are also generated by injection of the endonucleases TALEN or CRISPR/Cas9 into the pronucleus or cytoplasm of zygotes to produce gene KOs, knock-ins (KIs), conditional genes, or point mutations. There has been marked impact of the TGKSR on the science of SJCCC members. Researchers have gained insights from germline-transmitting chimeras of 41 different ESC-based targeted genes, and multiple founders of 34 DNA constructs during the current funding cycle. The TGKSR was used by 18 investigators of whom 83% (n=15/18) are members of the Cancer Center. Of these, 93% (n=14/15) hold cancer- focused peer-reviewed grants. These SJCCC members were drawn from 4 of 5 SJCCC Programs and yielded a combined total of 57 publications from CBP (n=26), NBTP (n=22), HMP (n=13), and DBSTP (n=1). During the upcoming cycle, in recognition of the growing impact of CRISPR/Cas9 reagents on advancing research performed by the SJCCC, the TGKSR will further enhance interactions with the new Center for Advanced Genome Engineering (CAGE) Shared Resource. We will create standardized workflows for bringing reagents designed by CAGE into the TGKSR and, in turn, for validating GEM tissue samples by CAGE in order to optimize GEM production. We will carry out pilot projects to test reagent modifications and concentrations to identify the most efficient and effective CRISPR approaches by comparing the efficiencies of pronuclear injections and cytoplasmic injections in zygotes. Our goal is to optimize these new reagents and their application in zygotes (to generate KOs, small KIs, point mutations, conditional alleles) and in ESCs (to generate large KIs and more involved conditional and inducible alleles) to most efficiently provide GEM to SJCCC members. Additionally, microinjection, surgery, and animal rooms of the TGKSR are slated to move to a new vivarium to be constructed on the St. Jude campus, with ground-breaking slated for spring 2018 and opening for 2021. Thorough planning of the scope and size of microinjection capabilities and animal space has been initiated to ensure that the future needs of SJCCC members for GEM production are met.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA021765-40
Application #
9632012
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2019-03-01
Budget End
2020-02-29
Support Year
40
Fiscal Year
2019
Total Cost
Indirect Cost
Name
St. Jude Children's Research Hospital
Department
Type
DUNS #
067717892
City
Memphis
State
TN
Country
United States
Zip Code
38105
Penkert, Rhiannon R; Hurwitz, Julia L; Thomas, Paul et al. (2018) Inflammatory molecule reduction with hydroxyurea therapy in children with sickle cell anemia. Haematologica 103:e50-e54
Turner, Benjamin L; Brenes-Arguedas, Tania; Condit, Richard (2018) Pervasive phosphorus limitation of tree species but not communities in tropical forests. Nature 555:367-370
Sadighi, Zsila S; Curtis, Elizabeth; Zabrowksi, Jennifer et al. (2018) Neurologic impairments from pediatric low-grade glioma by tumor location and timing of diagnosis. Pediatr Blood Cancer 65:e27063
Wierdl, Monika; Tsurkan, Lyudmila; Chi, Liying et al. (2018) Targeting ALK in pediatric RMS does not induce antitumor activity in vivo. Cancer Chemother Pharmacol 82:251-263
Pui, Ching-Hon; Liu, Yiwei; Relling, Mary V (2018) How to solve the problem of hypersensitivity to asparaginase? Pediatr Blood Cancer 65:
Mukkada, Sheena; Smith, Cristel Kate; Aguilar, Delta et al. (2018) Evaluation of a fever-management algorithm in a pediatric cancer center in a low-resource setting. Pediatr Blood Cancer 65:
Buchman, Cameron D; Chai, Sergio C; Chen, Taosheng (2018) A current structural perspective on PXR and CAR in drug metabolism. Expert Opin Drug Metab Toxicol 14:635-647
Gibbs, E B; Kriwacki, R W (2018) Direct detection of carbon and nitrogen nuclei for high-resolution analysis of intrinsically disordered proteins using NMR spectroscopy. Methods 138-139:39-46
Howell, Carrie R; Wilson, Carmen L; Ehrhardt, Matthew J et al. (2018) Clinical impact of sedentary behaviors in adult survivors of acute lymphoblastic leukemia: A report from the St. Jude Lifetime Cohort study. Cancer 124:1036-1043
Zamora, Anthony E; Crawford, Jeremy Chase; Thomas, Paul G (2018) Hitting the Target: How T Cells Detect and Eliminate Tumors. J Immunol 200:392-399

Showing the most recent 10 out of 6764 publications